Systemisk lupus erythematosus (SLE)

Dette dokumentet er basert på det profesjonelle dokumentet Systemisk lupus erytematosus. Referanselisten for dette dokumentet vises nedenfor.

1. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172(11):ITC81-ITC96. PMID: 32479157 PubMed 
2. Vaillant AAJ, Goyal A, Varacallo M. Systemic Lupus Erythematosus. StatPearls (Internet). Last Update: February 27, 2023. www.ncbi.nlm.nih.gov 
3. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD002922. The Cochrane Library 
4. Lerang K, Gilboe I, Garen T, et al. High incidence and prevalence of systemic lupus erythematosus in Norway. Lupus 2012; 21: 1362-9. pmid:22914817 PubMed 
5. Groot N, Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017. pmid:28630236 PubMed 
6. Moser, KL, Kelly, JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10: 373-9. doi:10.1038/gene.2009.39 DOI 
7. Lehmann P, Homey B. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev 2009; 8: 456-61. pmid:19167524 PubMed 
8. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78:1151. PubMed 
9. Aringer M, Brinks R, Dörner T, et al. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis 2021. pmid:33568386 PubMed 
10. Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 Jun. 164(6):1335-41. pmid: 21574972 PubMed 
11. Rubin RL. Drug-induced lupus. Expert Opin Drug Saf 2015; 14: 361-78. pmid:25554102 PubMed 
12. Gluhovschi C, Gluhovschi G, Petrica L, et al. Pregnancy Associated with Systemic Lupus Erythematosus: Immune Tolerance in Pregnancy and Its Deficiency in Systemic Lupus Erythematosus--An Immunological Dilemma. J Immunol Res 2015. pmid:26090485 PubMed 
13. Vu Lam N-C, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: Primary care approach to diagnosis and management. Am Fam Physician 2016; 94: 284-94. American Family Physician 
14. Kivity S, Agmon-Levin N, Zandman-Goddard G et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 2015; 13: 43. pmid:25858312 PubMed 
15. Joseph FG, Scolding NJ. Neurolupus. Pract Neurol 2010; 10: 4-15. pmid:20130291 PubMed 
16. Levy DM. Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis. UpToDate. Last updated Jun 24, 2022. www.uptodate.com 
17. Skorpen CG, Salvesen KÅB, Palm Ø, Radtke M, Wallenius M. Svangerskapskomplikasjoner hos kvinner med systemisk lupus erythematosus. Tidsskr Nor Legeforen 2021; 141: 758-60. pmid:34047174 PubMed 
18. Nasjonal kompetansetjeneste for svangerskap og revmatiske sykdommer (NKSR). Nasjonal veileder for svangerskap og revmatiske sykdommer. Trondheim; sist oppdatert mars 2018, siden besøkt 13.09.2018
19. Skorpen CG, Lydersen S, Gilboe IM et al. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis 2018; 77: 264-69. pmid:29092851 PubMed 
20. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012; 8: 439-53. pmid:22882219 PubMed 
21. Götestam Skorpen C, Lydersen S, Gilboe IM et al. Disease Activity During Pregnancy and the First Year Postpartum in Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2017; 69: 1201-08. pmid:27696790 PubMed 
22. Tincani A, Andreoli L, Chighizola C, Meroni PL. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity (2009) 42:257–9. DOI:10.1080/08916930902827918 DOI 
23. Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153-63. pmid:26098843 PubMed 
24. Yelnik CM, Laskin CA, Porter TF et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3(1): epub. pmid:26835148 PubMed 
25. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28(1):61–73. pmid:19932376 PubMed 
26. Willis R1, Seif AM, McGwin G Jr, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA, a multiethnic US cohort. Lupus 2012; 21: 830-5. pmid:22343096 PubMed 
27. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016 (Epub ahead of print). pmid:26888948 PubMed 
28. Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019. pmid:31092409 PubMed 
29. Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55: 1693-7. pmid:26750124 PubMed 
30. Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford) 2016; 55: 1698-702. pmid:26750125 PubMed 
31. Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476-85. pmid:27457513 PubMed 
32. Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016 Feb;45(4):463-70. PubMed 
33. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8. PubMed 
34. Barsalou J, Costedoat-Chalumeau N, Berhanu A et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis 2018; 77: 1742-49. pmid:30297329 PubMed 
35. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82. pmid:22626746 PubMed 
36. Gleicher N, Elkayam U. Preventing congenital heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies. A review of published literature and registered clinical trials. Autoimmune Rev 2013;12:1039-45. PMID: 23684701 PubMed 
37. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014 Mar;23(3):225-35. pmid:24399812 PubMed 
38. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31. PubMed 
39. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392: 222-31. pmid:30043749 PubMed 
40. Petri M, Bruce in, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 2023. pmid:36848919 PubMed 
41. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761-768. doi:10.1002/art.41179 DOI 
42. Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015. pmid:25777803 PubMed 
43. Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. Autoimmun Rev 2015. pmid:26427983 PubMed 
44. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD002922. The Cochrane Library 
45. Fischer-Betz R, Specker C, Brinks R, et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013; 52: 1070-6. pmid:23382355 PubMed 
46. Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah ÁN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD002265. DOI: 10.1002/14651858.CD002265.pub3. The Cochrane Library 
47. Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol 2013; 62: 255-62. pmid:23792700 PubMed 
48. Schramm AM, Clowse ME. Aspirin for prevention of preeklampsia i lupus pregnancy. Autoimmune Dis 2014. PMID: 24778868 PubMed 
49. Fischer-Betz R, Specker C. Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2017; 31: 397-414. pmid:29224680 PubMed 
50. Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 2014; 66: 608-16. pmid:24106157 PubMed 
51. Yafasova A, Fosbol EL, Schou M, et al. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. J Am Coll Cardiol. 2021 Apr 13;77(14):1717-1727. PMID: 33832598 PubMed 
52. Wallenius M, Salvesen KÅ, Daltveit AK, Skomsvoll JF. SLE and outcomes in first and subsequent births. Arthritis Care Res (Hoboken) 2014; 66: 1718-24. PubMed 
53. Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015;67(9):1237–1245. pmid:25777803 PubMed 
54. Skomsvoll JF, Wallenius M, Salvesen KÅ, Grindheim S. Inflammatoriske revmatiske sykdommer og kollagenoser. Veileder i fødselshjelp 2019. Norsk gynekologisk forening. legeforeningen.no